Date Title & Summary Additional Formats
August 31, 2022
Certara to Participate in Upcoming Investor Conferences
PRINCETON, N.J. , Aug. 31, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: • Morgan Stanley 20 th Annual Global Healthcare Conference   Date and Time:   Tuesday,
August 11, 2022
Certara Announces Secondary Offering
PRINCETON, N.J. , Aug. 11, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) (“Certara”), a global leader in biosimulation, today announced the sale by certain stockholders (the “Selling Stockholders”), including EQT Avatar Parent L.P. , in an underwritten secondary offering of 7,000,000 shares
August 9, 2022
Certara Reports Second Quarter 2022 Financial Results
Biosimulation software and services fuel second quarter growth PRINCETON, N.J. , Aug. 09, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2022 and adjusted its full year guidance.
August 5, 2022
Certara Introduces Update of Pinnacle 21™ Enterprise and New Pinnacle 21™ Data Exchange Module
New automation, analytics and collaboration features save time and ensure regulatory compliance PRINCETON, N.J. , Aug. 05, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the feature release 5.2.0 of Pinnacle 21 Enterprise, the Company’s
July 28, 2022
Certara Announces Collaboration with Leading Cancer Center to Advance CAR T-cell Therapies
Certara and Memorial Sloan Kettering Cancer Center to develop biosimulation platform for CAR T-cell therapies PRINCETON, N.J. , July 28, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a 2-year collaboration with Memorial Sloan Kettering
July 25, 2022
Certara Appoints Rosemary Crane as New Independent Board Member
PRINCETON, N.J. , July 25, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective July 21, 2022 . Her appointment brings the company’s board of directors to eleven members.
July 13, 2022
Certara Appoints Eran Broshy as New Independent Board Member
PRINCETON, N.J. , July 13, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Eran Broshy to its Board of Directors, effective July 11, 2022 . His appointment brings the company’s board of directors to ten members.
July 12, 2022
Certara to Report Second Quarter 2022 Financial Results on August 9th, 2022
PRINCETON, N.J. , July 12, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2022 after the market close on Tuesday, August 9 th , 2022.
June 28, 2022
Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development
Advances lead optimization, first-in-human dose prediction and formulation development PRINCETON, N.J. , June 28, 2022 (GLOBE NEWSWIRE) -- Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Discovery Simulator, a new software designed for scientists
June 21, 2022
Certara Announces New Versions of Biosimulation Software for Development of Novel Biologics
New capabilities enhance clinical predictability for different compounds across more therapeutic areas PRINCETON, N.J. , June 21, 2022 (GLOBE NEWSWIRE) -- Certara , a global leader in biosimulation, today announced the release of new versions of its Immunogenicity (IG), Immuno -oncology (IO) and
Displaying 1 - 10 of 17